---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002848"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:48:02.052563+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools reports preliminary FY2024 revenue ~$174M; Q4 ~$46.5M

## Summary
- Preliminary Q4 2024 revenue approximately $46.5 million.
- Full year 2024 revenue approximately $174 million, at top end of revised guidance.
- CEO cites industry-wide headwinds and progress reducing operating expenses via SBS.
- Company to discuss 2025 outlook when reporting final Q4/FY results later in Q1 2025.

## SEC filing metadata
- accession: 0001104659-25-002848
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000110465925002848/0001104659-25-002848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000110465925002848/tm252898d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002848
- JSON: https://secwatch.observer/filing/0001104659-25-002848.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.